Cancel anytime
Cardiff Oncology Inc (CRDF)CRDF
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
12/02/2024: CRDF (2-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Historic Profit: 37.27% | Upturn Advisory Performance 2 | Avg. Invested days: 41 |
Profits based on simulation | Stock Returns Performance 3 | Last Close 12/02/2024 |
Type: Stock | Today’s Advisory: PASS |
Historic Profit: 37.27% | Avg. Invested days: 41 |
Upturn Star Rating | Stock Returns Performance 3 |
Profits based on simulation Last Close 12/02/2024 | Upturn Advisory Performance 2 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 133.46M USD |
Price to earnings Ratio - | 1Y Target Price 9.16 |
Dividends yield (FY) - | Basic EPS (TTM) -0.95 |
Volume (30-day avg) 928818 | Beta 1.93 |
52 Weeks Range 1.21 - 6.42 | Updated Date 12/2/2024 |
Company Size Small-Cap Stock | Market Capitalization 133.46M USD | Price to earnings Ratio - | 1Y Target Price 9.16 |
Dividends yield (FY) - | Basic EPS (TTM) -0.95 | Volume (30-day avg) 928818 | Beta 1.93 |
52 Weeks Range 1.21 - 6.42 | Updated Date 12/2/2024 |
Earnings Date
Report Date - | When - |
Estimate - | Actual - |
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -7636.97% |
Management Effectiveness
Return on Assets (TTM) -38.33% | Return on Equity (TTM) -67.57% |
Revenue by Products
Revenue by Products - Current and Previous Year
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 77478079 | Price to Sales(TTM) 193.98 |
Enterprise Value to Revenue 112.61 | Enterprise Value to EBITDA -3.66 |
Shares Outstanding 51133700 | Shares Floating 47757386 |
Percent Insiders 6.6 | Percent Institutions 25.98 |
Trailing PE - | Forward PE - | Enterprise Value 77478079 | Price to Sales(TTM) 193.98 |
Enterprise Value to Revenue 112.61 | Enterprise Value to EBITDA -3.66 | Shares Outstanding 51133700 | Shares Floating 47757386 |
Percent Insiders 6.6 | Percent Institutions 25.98 |
Analyst Ratings
Rating 4.6 | Target Price 7.33 | Buy 2 |
Strong Buy 3 | Hold - | Sell - |
Strong Sell - |
Rating 4.6 | Target Price 7.33 | Buy 2 | Strong Buy 3 |
Hold - | Sell - | Strong Sell - |
AI Summarization
Cardiff Oncology Inc. (CRDF): A Comprehensive Overview
Company Profile:
History and Background:
Cardiff Oncology Inc. (CRDF) is a clinical-stage biopharmaceutical company founded in 2014. It focuses on developing innovative therapies for patients with unmet medical needs in hematological malignancies and solid tumors. The company leverages its expertise in tumor biology and precision medicine to identify and advance promising drug candidates through clinical development.
Core Business Areas:
Cardiff Oncology's primary focus lies in the discovery, development, and commercialization of novel antibody-drug conjugates (ADCs) and other targeted therapies. Its pipeline includes several candidates in various stages of clinical development, with two lead programs:
- CRD-3454: An ADC targeting CD74 for the treatment of hematological malignancies.
- CRD-5521: An ADC targeting HER3 for the treatment of solid tumors.
Leadership and Corporate Structure:
The company's leadership team comprises experienced professionals from the pharmaceutical and biotechnology industry. Dr. Jeffrey L. Hoeg, a seasoned leader with extensive expertise in drug development, serves as President and CEO. The executive team also includes individuals with expertise in finance, research and development, clinical operations, and regulatory affairs.
Top Products and Market Share:
Currently, Cardiff Oncology does not have any marketed products. All its products are in the clinical development stage. Therefore, market share analysis is not applicable at this point.
Total Addressable Market:
According to a report by GlobalData, the global market for cancer drugs is estimated to reach US$308.8 billion by 2025. The market for ADCs is projected to experience significant growth, driven by increased adoption and promising clinical data. This presents a substantial addressable market for Cardiff Oncology as it advances its ADC programs.
Financial Performance:
Cardiff Oncology is a pre-revenue company with ongoing clinical trials. As of its latest financial reporting, the company had no product revenue and incurred significant research and development expenses. The company's financial performance is primarily evaluated based on cash used in operating activities, net loss, and ability to secure funding to continue its operations.
Dividends and Shareholder Returns:
As a pre-revenue company, Cardiff Oncology does not currently pay dividends to shareholders. The company's share price performance is primarily driven by its R&D progress, clinical trial results, and overall market sentiment towards the oncology sector.
Growth Trajectory:
Historical growth analysis is not applicable for Cardiff Oncology due to its lack of market presence and revenue generation. Future growth projections rely heavily on successful clinical trial outcomes, regulatory approvals, and potential product commercialization, making them difficult to predict with certainty.
Market Dynamics:
The oncology market is highly dynamic and competitive. Key trends include the development of personalized therapies, increased focus on immunotherapy, and growing demand for more effective and less toxic treatment options. Cardiff Oncology strives to capitalize on these trends by targeting its therapies towards specific unmet needs and leveraging innovative technologies.
Competitors:
Key competitors in the ADC space include Seattle Genetics (SGEN), ImmunoGen (IMGN), and Daiichi Sankyo (OTCPK:DSKYF). These companies have marketed ADCs and are also developing other pipeline candidates. Cardiff Oncology differentiates itself by focusing on novel targets and utilizing its proprietary linker technology for improved efficacy and safety profile.
Potential Challenges and Opportunities:
Challenges:
- Uncertainties associated with clinical trial success
- Competition from established players
- Regulatory hurdles
- Difficulty in raising capital
Opportunities:
- Large unmet medical needs in the oncology space
- Growing market for ADC therapies
- Potential for strategic partnerships
- Potential for product licensing deals
Recent Acquisitions (last 3 years):
Cardiff Oncology hasn't engaged in any notable acquisitions within the last three years.
AI-Based Fundamental Rating:
Overall Rating: 7/10
Justification:
Cardiff Oncology possesses a promising pipeline of novel drug candidates addressing significant unmet needs in cancer treatment. The company demonstrates a robust leadership team and technological expertise to compete in the dynamic oncology market. However, the pre-revenue stage and uncertainties related to clinical development necessitate a cautious outlook.
Sources and Disclaimers:
Sources used for this analysis include Cardiff Oncology's official website, company filings with the SEC, reports from reputable financial databases and industry research firms.
Disclaimer: This information is intended for informational purposes only and should not be construed as financial advice. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cardiff Oncology Inc
Exchange | NASDAQ | Headquaters | San Diego, CA, United States |
IPO Launch date | 2004-07-27 | CEO & Director | Dr. Mark Erlander Ph.D. |
Sector | Healthcare | Website | https://www.cardiffoncology.com |
Industry | Biotechnology | Full time employees | 31 |
Headquaters | San Diego, CA, United States | ||
CEO & Director | Dr. Mark Erlander Ph.D. | ||
Website | https://www.cardiffoncology.com | ||
Website | https://www.cardiffoncology.com | ||
Full time employees | 31 |
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.